Trial Profile
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-Ligand 1 (PD-L1) Antibody (BMS-936559) in Subjects With Relapsed or Refractory Hematologic Malignancy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 936559 (Primary)
- Indications Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Biomarker
- 22 Feb 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 17 Oct 2011 New trial record